Amy H. Huang, Hematology Oncology Fellow at The University of Connecticut, shared a post on X:
“Excited to share our work at ASH! This is a bi-institutional study (UConn and Yale) on bone health in myeloma that has been recognized with the ASH Abstract Achievement Award.
- Delays in dental screening are a major contributor to guideline nonadherence of bone-modifying agent (BMA) prescriptions. Opportunity for QI initiatives to streamline the process.
- Only around 56% of BMA prescriptions were fully concordant with the IMWG guidelines.
- The occurrence of skeletal events was also found to be similar between patients who received more than 5 years of BMA versus less than 5 years. This raises the question of whether prolonged use of BMA really confers benefit and further research is needed.
Managing morbidities is as important as treating the malignancy itself. Sometimes this is what patients care about the most.”
More posts featuring Amy H. Huang.